‘I Didn’t Want to Be on Medication the Rest of My Life’: Veteran Runs Psilocybin Retreats for PTSD Before FDA Approval

Why It Matters

Veterans face a suicide rate more than twice the national average, and psychedelic‑assisted therapy could offer a faster, non‑pharmaceutical option. State‑level legalization may accelerate treatment availability while federal approval lags, reshaping mental‑health care for a high‑risk population.

Key Takeaways

• Heroic Hearts Project served over 1,500 veterans; waiting list exceeds 2,000
• Colorado, New Mexico, Oregon permit therapeutic psilocybin; eight states eye bills
• 2025 trial with 22 PTSD adults found psilocybin safe, symptom relief
• Veteran suicide rate 35 per 100k, over twice the U.S. average
• Advocates push state‑level access, citing urgent need before FDA approval

Pulse Analysis

The mental‑health crisis among U.S. veterans has intensified as suicide rates climb to 35 per 100,000—more than double that of the general population. Traditional pharmacotherapy often serves as a maintenance regimen rather than a cure, prompting veterans like Jesse Gould to explore psychedelic alternatives. Gould’s Heroic Hearts Project, launched in 2017, pairs rigorous screening with guided psilocybin or ayahuasca sessions, reporting no psychotic episodes among its 1,500+ participants and a growing waiting list that underscores unmet demand.

State legislatures are responding to this pressure. Colorado, New Mexico and Oregon have already legalized psilocybin for therapeutic use, and bipartisan bills are moving forward in at least eight other states, including Minnesota and New York. Proponents argue that controlled, state‑regulated access can save lives now, while critics urge caution until the FDA completes its approval pathway. A 2025 Journal of Psychopharmacology study involving 22 PTSD patients demonstrated that psilocybin, when administered with professional support, is well‑tolerated and linked to measurable symptom reduction, adding empirical weight to policy debates.

The convergence of clinical evidence, veteran advocacy, and evolving state policies signals a potential market shift. Pharmaceutical firms and mental‑health providers are likely to invest in psychedelic research and infrastructure, anticipating a post‑FDA approval boom. Meanwhile, nonprofits like Heroic Hearts will continue to fill the gap, refining intake protocols and integration practices that could become industry standards. As the regulatory landscape solidifies, stakeholders must balance rapid access with safety safeguards to ensure that the promise of psychedelic therapy translates into lasting, scalable outcomes for veterans and the broader population.